IBEX Form 4: CEO Robert Dechant Logs $150K Insider Sale

Rhea-AI Filing Summary

IBEX Ltd (IBEX) Form 4 filing discloses two open-market sales by Chief Executive Officer and Director Robert Thomas Dechant on 2 and 3 July 2025. The transactions involved a total of 5,000 common shares sold at $30.00 per share, producing proceeds of roughly $150,000. Following the dispositions, Dechant’s direct ownership declined from 198,633 to 193,633 shares, a reduction of about 2.5% of his previously held stake. No derivative security activity was reported, and the filing was submitted individually on 3 July 2025.

The modest size of the sale relative to Dechant’s remaining holdings suggests routine portfolio management rather than a wholesale change in insider sentiment. Nonetheless, any CEO sale can attract investor attention, particularly when not explicitly tied to a pre-arranged 10b5-1 trading plan (the form does not indicate such a plan was in place).

Positive

• CEO retains a substantial 193,633-share position, indicating continued equity alignment with shareholders.
• Prompt disclosure via Form 4 enhances transparency around insider transactions.

Negative

• Insider sale of 5,000 shares (~2.5% of holdings) may raise modest concern about near-term confidence.
• No 10b5-1 plan indicated, suggesting discretionary timing of the sales.

Insights

Securities Analyst

TL;DR: CEO sells 5,000 shares (≈2.5%)—small, likely immaterial, but worth monitoring.

The transaction totals about $150k and leaves Robert Dechant with more than 193k shares, maintaining significant alignment with shareholders. The absence of any 10b5-1 notation means the sales were discretionary, yet the limited size relative to his stake and IBEX’s public float points to low materiality. For most investors, this is a neutral governance datapoint rather than a valuation catalyst, though persistent insider selling could signal growing caution if it continues.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dechant Robert Thomas

(Last) (First) (Middle)

C/O IBEX LIMITED

1717 PENNSYLVANIA AVENUE NW, SUITE 825

(Street)

WASHINGTON DC 20006

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IBEX Ltd [ IBEX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Shares	07/02/2025		S		624	D	$30	198,009	D
Common Shares	07/03/2025		S		4,376	D	$30	193,633	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

	Lisa Lenstrohm, Attorney-in-Fact	07/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many IBEX shares did CEO Robert Dechant sell?

He sold a total of 5,000 common shares (624 on 07/02/2025 and 4,376 on 07/03/2025).

At what price were the IBEX shares sold?

Both transactions were reported at $30.00 per share.

How many IBEX shares does the CEO still own after the sale?

After the reported sales, Dechant directly holds 193,633 common shares.

Was the sale made under a Rule 10b5-1 trading plan?

The Form 4 does not indicate that the transactions were executed under a 10b5-1 plan.

Does this insider sale significantly impact IBEX’s outlook?

Given the sale represents roughly 2.5% of the CEO’s holdings, it is generally viewed as low-impact for the company’s fundamentals.